- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Immunovaccine To Present New Data At The AACR Annual Meeting
Immunovaccine (TSX:IMV, OTCQX:IMMVF) announced it will present a new set of pre-clinical data on DepoVax-based vaccines for cancer on the American Association for Cancer Research Annual Meeting, in April.
Immunovaccine (TSX:IMV, OTCQX:IMMVF) announced it will present a new set of pre-clinical data on DepoVax-based vaccines for cancer on the American Association for Cancer Research Annual Meeting, in April.
As quoted in the press release:
Immunovaccine conducted this research in collaboration with Peregrine Pharmaceuticals (NASDAQ:PPHM) with the goal of analyzing the potential enhanced anti-cancer activity of combining DepoVax™-based cancer immunotherapies with Peregrine’s lead clinical product candidate bavituximab, an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS).
Details of the presentation are as follows:
Title: Phosphatidylserine-Targeting Antibodies Enhance Anti-tumor Activity of a Tumor Vaccine in a HPV-Induced Tumor Model
Date and time: Tuesday, April 4, 8:00 AM – 12:00 PM ET
Abstract number: 3657
Location: Section 26
Poster board number: 30
Immunovaccine Director of Research Dr. Genevieve Weir will present data analyzing the potential for enhanced anti-tumor responses of PS and PD-1 targeting antibody therapies when combined with an HPV16 peptide vaccine formulated in Immunovaccine’s proprietary DepoVax™ technology.
“Our work with Peregrine, and the research it has produced, fits squarely into our corporate objective of exploring clinical stage immunotherapies that may have synergistic effects when combined with our lead candidate, DPX-Survivac,” said Marianne Stanford, PhD Vice President, Research for Immunovaccine. “We look forward to discussing the results of this study, and its potential implications, with our colleagues in the scientific community at this year’s AACR meeting.”
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. An investigator-sponsored Phase 2 study is currently assessing the safety and efficacy of DPX-Survivac combined with an approved anti-PD-1 drug in advanced ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. The Company also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.